Curemark - Biopharmaceutical Developments

Clinical Trials

We are focused on finding innovative solutions to unmet medical needs. We have completed pivotal studies for CM-AT, our drug candidate for Autism Spectrum Disorder (ASD) and have a pipeline of novel therapeutics addressing enzyme deficiencies in a broad range of neurological indications.

AUTISM

Autism

We’re working to bring CM-AT, a first-in-class Autism treatment to market. We believe CM-AT has the potential to affect both core and non-core symptoms in children with Autism. Take a closer look at what we’ve discovered and learn more about our novel approach.

Learn More

ABOUT US

About Us

Founded in 2007, Curemark is a private, clinical-stage biopharmaceutical company developing novel therapies for the treatment of serious unmet needs in neuro-developmental and neurodegenerative disorders. Curemark has a robust pipeline including their lead drug candidate, CM-AT, the first and only disorder-modifying therapy for Autism.

Learn More

Technology

We are developing breakthrough technologies that shed light on key connections that factor into neurological diseases. We’ve discovered a critical link between enzymes, the pancreas and neurological conditions. We’re approaching treatment with a revolutionary method of drug delivery.

Learn more

OUR STORY

Our Story

What started as one doctor’s observation has expanded into a broad pipeline of potential therapies that may significantly affect neurological diseases. We have conducted important research, made discoveries and are disrupting conventional thinking. Learn more about our story.

Learn More